Thyroid Cancer Drugs Market Size to Jump at US$4.3 billion by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Thyroid Cancer Drugs Market Size Analysis

Global Thyroid Cancer Drugs Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Papillary Thyroid Cancer
    1. By Value
  3. Follicular Thyroid Cancer
    1. By Value
  4. Hurthle Cell Cancer
    1. By Value
  5. Medullary Thyroid Cancer (MTC)
    1. By Value
  6. Anaplastic Thyroid Cancer
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Medication
    1. By Value
  3. Chemotherapy
    1. By Value
  4. Radioactive Iodine (Radioiodine) Therapy
    1. By Value
  5. Hormone Therapy
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Thyroid Desiccated
    1. By Value
  3. Sorafenib
    1. By Value
  4. Thyrotropin Alfa
    1. By Value
  5. Vandetanib
    1. By Value
  6. Doxorubicin
    1. By Value
  7. Cabozantinib
    1. By Value
  8. Lenvatini
    1. By Value
  9. Sodium Iodide I-131
    1. By Value
  10. Dabrafenib
    1. By Value
  11. Trametinib
    1. By Value
  12. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
5. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Papillary Thyroid Cancer
    1. By Value
  3. Follicular Thyroid Cancer
    1. By Value
  4. Hurthle Cell Cancer
    1. By Value
  5. Medullary Thyroid Cancer (MTC)
    1. By Value
  6. Anaplastic Thyroid Cancer
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Medication
    1. By Value
  3. Chemotherapy
    1. By Value
  4. Radioactive Iodine (Radioiodine) Therapy
    1. By Value
  5. Hormone Therapy
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Thyroid Desiccated
    1. By Value
  3. Sorafenib
    1. By Value
  4. Thyrotropin Alfa
    1. By Value
  5. Vandetanib
    1. By Value
  6. Doxorubicin
    1. By Value
  7. Cabozantinib
    1. By Value
  8. Lenvatini
    1. By Value
  9. Sodium Iodide I-131
    1. By Value
  10. Dabrafenib
    1. By Value
  11. Trametinib
    1. By Value
  12. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
5. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Papillary Thyroid Cancer
    1. By Value
  3. Follicular Thyroid Cancer
    1. By Value
  4. Hurthle Cell Cancer
    1. By Value
  5. Medullary Thyroid Cancer (MTC)
    1. By Value
  6. Anaplastic Thyroid Cancer
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Medication
    1. By Value
  3. Chemotherapy
    1. By Value
  4. Radioactive Iodine (Radioiodine) Therapy
    1. By Value
  5. Hormone Therapy
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Thyroid Desiccated
    1. By Value
  3. Sorafenib
    1. By Value
  4. Thyrotropin Alfa
    1. By Value
  5. Vandetanib
    1. By Value
  6. Doxorubicin
    1. By Value
  7. Cabozantinib
    1. By Value
  8. Lenvatini
    1. By Value
  9. Sodium Iodide I-131
    1. By Value
  10. Dabrafenib
    1. By Value
  11. Trametinib
    1. By Value
  12. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
5. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Papillary Thyroid Cancer
    1. By Value
  3. Follicular Thyroid Cancer
    1. By Value
  4. Hurthle Cell Cancer
    1. By Value
  5. Medullary Thyroid Cancer (MTC)
    1. By Value
  6. Anaplastic Thyroid Cancer
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Medication
    1. By Value
  3. Chemotherapy
    1. By Value
  4. Radioactive Iodine (Radioiodine) Therapy
    1. By Value
  5. Hormone Therapy
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Thyroid Desiccated
    1. By Value
  3. Sorafenib
    1. By Value
  4. Thyrotropin Alfa
    1. By Value
  5. Vandetanib
    1. By Value
  6. Doxorubicin
    1. By Value
  7. Cabozantinib
    1. By Value
  8. Lenvatini
    1. By Value
  9. Sodium Iodide I-131
    1. By Value
  10. Dabrafenib
    1. By Value
  11. Trametinib
    1. By Value
  12. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
5. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Papillary Thyroid Cancer
  1. By Value
3. Follicular Thyroid Cancer
  1. By Value
4. Hurthle Cell Cancer
  1. By Value
5. Medullary Thyroid Cancer (MTC)
  1. By Value
6. Anaplastic Thyroid Cancer
  1. By Value
By Treatment
1. Introduction
  1. Treatment By Value
2. Medication
  1. By Value
3. Chemotherapy
  1. By Value
4. Radioactive Iodine (Radioiodine) Therapy
  1. By Value
5. Hormone Therapy
  1. By Value
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Thyroid Desiccated
  1. By Value
3. Sorafenib
  1. By Value
4. Thyrotropin Alfa
  1. By Value
5. Vandetanib
  1. By Value
6. Doxorubicin
  1. By Value
7. Cabozantinib
  1. By Value
8. Lenvatini
  1. By Value
9. Sodium Iodide I-131
  1. By Value
10. Dabrafenib
  1. By Value
11. Trametinib
  1. By Value
12. Others
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Oral
  1. By Value
3. Injectable
  1. By Value
4. Others
  1. By Value
By End-Users
1. Introduction
  1. End-Users By Value
2. Hospitals
  1. By Value
3. Homecare
  1. By Value
4. Specialty Clinics
  1. By Value
5. Others
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Papillary Thyroid Cancer
    1. By Value
  3. Follicular Thyroid Cancer
    1. By Value
  4. Hurthle Cell Cancer
    1. By Value
  5. Medullary Thyroid Cancer (MTC)
    1. By Value
  6. Anaplastic Thyroid Cancer
    1. By Value
2. By Treatment
  1. Introduction
    1. Treatment By Value
  2. Medication
    1. By Value
  3. Chemotherapy
    1. By Value
  4. Radioactive Iodine (Radioiodine) Therapy
    1. By Value
  5. Hormone Therapy
    1. By Value
3. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Thyroid Desiccated
    1. By Value
  3. Sorafenib
    1. By Value
  4. Thyrotropin Alfa
    1. By Value
  5. Vandetanib
    1. By Value
  6. Doxorubicin
    1. By Value
  7. Cabozantinib
    1. By Value
  8. Lenvatini
    1. By Value
  9. Sodium Iodide I-131
    1. By Value
  10. Dabrafenib
    1. By Value
  11. Trametinib
    1. By Value
  12. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Oral
    1. By Value
  3. Injectable
    1. By Value
  4. Others
    1. By Value
5. By End-Users
  1. Introduction
    1. End-Users By Value
  2. Hospitals
    1. By Value
  3. Homecare
    1. By Value
  4. Specialty Clinics
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Thyroid Cancer Drugs Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Mylan N.V.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd
Jerome Stevens Pharmaceuticals Inc
Baxter
Abbott
Celgene Corporation
AstraZeneca
GlaxoSmithKline plc
Eisai Co. Ltd
Takeda Pharmaceutical Company Ltd
Biovista
Cytori Therapeutics Inc
Bayer AG
Novartis AG
Bio-Path Holdings Inc.
Vascular Biogenics

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment